Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846312 · ClinicalTrials.gov registry record
An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 40
- Enrollment target
NCT01846312: Completed study, sponsored by Novo Nordisk A/S.
NCT01846312 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01846312 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
This study is conducted in the United States of America (USA). The aim of the study is to assess longitudinal variation of immune biomarkers in subjects at risk for development of type 1 diabetes (T1D).
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-09 |
What the finished NCT01846312 record still lists
NCT01846312 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT01846312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01846312 about?
NCT01846312 is a clinical study titled "An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes". This study is conducted in the United States of America (USA). The aim of the study is to assess longitudinal variation of immune biomarkers in subjects at risk for development of type 1 diabetes (T1D).
What is the current status of trial NCT01846312?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2013-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01846312?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT01846312?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia